3/17
02:57 pm
kros
KROS Stock: What to Know About Rinvatercept in DMD [Yahoo! Finance]
Low
Report
KROS Stock: What to Know About Rinvatercept in DMD [Yahoo! Finance]
3/9
08:00 am
kros
Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS
Low
Report
Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS
3/9
08:00 am
kros
Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference
Low
Report
Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference
3/5
11:44 am
kros
Keros Therapeutics (KROS) had its price target lowered by Wells Fargo & Company from $23.00 to $20.00. They now have an "overweight" rating on the stock.
Medium
Report
Keros Therapeutics (KROS) had its price target lowered by Wells Fargo & Company from $23.00 to $20.00. They now have an "overweight" rating on the stock.
3/4
04:01 pm
kros
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
High
Report
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
2/26
04:01 pm
kros
Keros Therapeutics Appoints Charles Newton to its Board of Directors
Medium
Report
Keros Therapeutics Appoints Charles Newton to its Board of Directors
2/18
04:01 pm
kros
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
Low
Report
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences